[Selected CD34+ cell autologous transplantation for advanced malignant tumors].
OBJECTIVE
To determine the clinical results of selected CD34(+) cell autologous transplantation in advanced malignant tumors.


METHODS
After pretreatment, fifteen patients aged 12 - 70 (49.5) years with various Stage III or IV malignant tumors were given the sorted CD34(+) cells collected by magnetic-activated cell sorting (Clini MACS, Milteny Biotech, Germany).


RESULTS
Peripheral blood progenitor cells (PBPC) from the patients were mobilized by chemotherapy and G-CSF 5 micro g/kg per day. CD34(+) cells gave 2.0 - 5 log depletion after cell sorting, with a median yield of CD34(+) selected cells of 2.4 (0.15 - 12.03) x 10(6)/kg. It gave a median recovery of 64 (52 - 81.4)% and median purity of 98.2 (83.2 - 99.7)%. The median time of neutrophil recovery > 1.0 x 10(9)/L and platelet recovery > 20 x 10(9)/L post-transplantation were 14 (8 - 26) days and 13 (11 - 35) days, respectively. On follow-up of 2 - 33 (11) months, the event-free survival rate was 53.3% (8/15) and the overall survival rate was 66.7% (10/15).


CONCLUSIONS
Transplantation of autologous selected PBPC CD34(+) cells gives prompt and stable engraftment. Selected CD34(+) cell transplantation, being a safe approach, may improve the clinical outcome even in patients with advanced malignant tumors.
Dong
Lu-jia
LJ
Hematopoietic Cell Transplantation Center, North Taiping Hospital, Beijing 100039, China.
Chen
Hu
H
Jiang
Min
M
Hu
Liang-ding
LD
Qin
Mao-quan
MQ
Zhang
Wei-jing
WJ
Yu
Zhi-yong
ZY
Wu
Shi-kai
SK
Chen
Xi-lin
XL
Bao
Yun-hua
YH
Song
San-tai
ST
Liu
Duan-qi
DQ
D000293:Adolescent; D000328:Adult; D000368:Aged; D018952:Antigens, CD34 / Q000032:analysis*; D002648:Child; D005260:Female; D018380:Hematopoietic Stem Cell Transplantation / Q000009:adverse effects; D006801:Humans; D008297:Male; D008875:Middle Aged; D009369:Neoplasms / Q000401:mortality / Q000628:therapy*; D015996:Survival Rate; D014182:Transplantation, Autologous
D018952:Antigens, CD34